drugset / Trial / NCT03188445
Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.
RandomizedParallel-groupOpen-labelTreatment
Summary
Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy
Timeline
- Start
- 2017-07-11
- Primary completion
- 2020-06-26
- Completion
- 2020-08-18
Publications
- Hansen R, Sommer VM, Pinborg A, Krebs L, Thomsen LL, Moos T, Holm C. Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial. Arch Gynecol Obstet. 2023 Oct;308(4):1165-1173. doi: 10.1007/s00404-022-06768-x. Epub 2022 Sep 15.
- Markova V, Hansen R, Thomsen LL, Pinborg A, Moos T, Holm C. Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial. Trials. 2020 Aug 26;21(1):742. doi: 10.1186/s13063-020-04637-z.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric Derisomaltose | Unknown | 1000 mg | Intravenous |
| Comparator | Ferrous Sulfate | Diagnostic / imaging agent | 100 mg | Oral |
| Comparator | Vitamin C | Other / unclassified | 60 mg | Oral |